[96a5a0]: / output / allTrials / identified / NCT02973672_identified.json

Download this file

601 lines (601 with data), 26.7 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
{
"info": {
"nct_id": "NCT02973672",
"official_title": "A Phase I Study Assessing the Safety and Performance of SGM-101, a Fluorochrome-labeled Anti-carcino-embryonic Antigen Monoclonal Antibody for the Detection of Neoplastic Lesions in Patients With Colorectal Cancer or Pancreatic Cancer",
"inclusion_criteria": "* Patients aged over 18 years old;\n* Patient should be scheduled and eligible for surgery because of a clinical diagnosis of cancer of the colon, rectum or cancer of the pancreas;\n* Both pancreatic and colorectal cancer patients: Circulating plasma CEA ≥ the upper limit of normal range (eg ≥ 3.0 ng / ml);\n* Patient suffering from recurrences and metastasis of colorectal cancer: Rising circulating plasma CEA\n* Patients should be capable and willing to give informed consent before study specific procedures.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Anticancer therapy (e.g. chemotherapy, radiotherapy (except for routine pre-operative radiotherapy for colorectal cancer), targeted therapy, concomitant systemic immune therapy, or any experimental therapy) within 4 weeks before inclusion;\n* History of a clinically significant allergy;\n* Circulating plasma concentration CEA ≥ 300 ng / ml;\n* Other malignancies either currently active or diagnosed in the last 5 years, except adequately treated in situ carcinoma of the cervix and basal or squamous cell skin carcinoma;\n* Patients pregnant or breastfeeding (pregnancy should be ruled out by an assay of βhCG plasma within 4±1 weeks prior to administration of the conjugate), lack of effective contraception in male or female patients with reproductive potential;\n* Laboratory abnormalities defined as:\n\nColorectal cancer patients only:\n\n* Aspartate AminoTransferase, Alanine AminoTransferase, Gamma Glutamyl Transferase) or Alkaline Phosphatase levels above 5 times the or;\n* Total bilirubin above 2 times the Upper Limit Normal (ULN) or; Both pancreatic and colorectal cancer patients:\n* Serum creatinine above 1.5 times the ULN or;\n* Absolute neutrophils counts below 1.5 x 109/L or;\n* Platelet count below 100 x 109/L or;\n* Hemoglobin below 4 mmol/L (females) or below 5 mmol/l (males);\n* Known positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAG) or hepatitis C virus (HCV) antibody or patients with untreated serious infections;\n* Any condition that the investigator considers to be potentially jeopardizing the patients' wellbeing or the study objectives.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Patients aged over 18 years old;",
"criterions": [
{
"exact_snippets": "Patients aged over 18 years old",
"criterion": "age",
"requirements": [
{
"requirement_type": "N/A",
"expected_value": {
"operator": ">",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "* Patient should be scheduled and eligible for surgery because of a clinical diagnosis of cancer of the colon, rectum or cancer of the pancreas;",
"criterions": [
{
"exact_snippets": "eligible for surgery",
"criterion": "surgery eligibility",
"requirements": [
{
"requirement_type": "eligibility",
"expected_value": true
}
]
},
{
"exact_snippets": "clinical diagnosis of cancer of the colon",
"criterion": "colon cancer diagnosis",
"requirements": [
{
"requirement_type": "diagnosis",
"expected_value": true
}
]
},
{
"exact_snippets": "clinical diagnosis of ... rectum",
"criterion": "rectal cancer diagnosis",
"requirements": [
{
"requirement_type": "diagnosis",
"expected_value": true
}
]
},
{
"exact_snippets": "clinical diagnosis of ... cancer of the pancreas",
"criterion": "pancreatic cancer diagnosis",
"requirements": [
{
"requirement_type": "diagnosis",
"expected_value": true
}
]
}
]
},
{
"line": "* Both pancreatic and colorectal cancer patients: Circulating plasma CEA ≥ the upper limit of normal range (eg ≥ 3.0 ng / ml);",
"criterions": [
{
"exact_snippets": "pancreatic and colorectal cancer patients",
"criterion": "cancer type",
"requirements": [
{
"requirement_type": "presence",
"expected_value": [
"pancreatic",
"colorectal"
]
}
]
},
{
"exact_snippets": "Circulating plasma CEA ≥ the upper limit of normal range (eg ≥ 3.0 ng / ml)",
"criterion": "circulating plasma CEA",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">=",
"value": 3.0,
"unit": "ng/ml"
}
}
]
}
]
},
{
"line": "* Patient suffering from recurrences and metastasis of colorectal cancer: Rising circulating plasma CEA",
"criterions": [
{
"exact_snippets": "recurrences and metastasis of colorectal cancer",
"criterion": "colorectal cancer",
"requirements": [
{
"requirement_type": "condition",
"expected_value": "recurrences and metastasis"
}
]
},
{
"exact_snippets": "Rising circulating plasma CEA",
"criterion": "circulating plasma CEA",
"requirements": [
{
"requirement_type": "trend",
"expected_value": "rising"
}
]
}
]
},
{
"line": "* Patients should be capable and willing to give informed consent before study specific procedures.",
"criterions": [
{
"exact_snippets": "capable and willing to give informed consent",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "capability",
"expected_value": true
},
{
"requirement_type": "willingness",
"expected_value": true
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Anticancer therapy (e.g. chemotherapy, radiotherapy (except for routine pre-operative radiotherapy for colorectal cancer), targeted therapy, concomitant systemic immune therapy, or any experimental therapy) within 4 weeks before inclusion;",
"criterions": [
{
"exact_snippets": "Anticancer therapy (e.g. chemotherapy, radiotherapy ... targeted therapy, concomitant systemic immune therapy, or any experimental therapy) within 4 weeks before inclusion",
"criterion": "anticancer therapy",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* History of a clinically significant allergy;",
"criterions": [
{
"exact_snippets": "History of a clinically significant allergy",
"criterion": "clinically significant allergy",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
},
{
"line": "* Circulating plasma concentration CEA ≥ 300 ng / ml;",
"criterions": [
{
"exact_snippets": "Circulating plasma concentration CEA ≥ 300 ng / ml",
"criterion": "circulating plasma concentration CEA",
"requirements": [
{
"requirement_type": "concentration",
"expected_value": {
"operator": ">=",
"value": 300,
"unit": "ng/ml"
}
}
]
}
]
},
{
"line": "* Other malignancies either currently active or diagnosed in the last 5 years, except adequately treated in situ carcinoma of the cervix and basal or squamous cell skin carcinoma;",
"criterions": [
{
"exact_snippets": "Other malignancies either currently active",
"criterion": "other malignancies",
"requirements": [
{
"requirement_type": "activity",
"expected_value": true
}
]
},
{
"exact_snippets": "Other malignancies ... diagnosed in the last 5 years",
"criterion": "other malignancies",
"requirements": [
{
"requirement_type": "diagnosis time frame",
"expected_value": {
"operator": "<=",
"value": 5,
"unit": "years"
}
}
]
},
{
"exact_snippets": "adequately treated in situ carcinoma of the cervix",
"criterion": "in situ carcinoma of the cervix",
"requirements": [
{
"requirement_type": "treatment adequacy",
"expected_value": true
}
]
},
{
"exact_snippets": "adequately treated ... basal or squamous cell skin carcinoma",
"criterion": "basal or squamous cell skin carcinoma",
"requirements": [
{
"requirement_type": "treatment adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "* Patients pregnant or breastfeeding (pregnancy should be ruled out by an assay of βhCG plasma within 4±1 weeks prior to administration of the conjugate), lack of effective contraception in male or female patients with reproductive potential;",
"criterions": [
{
"exact_snippets": "Patients pregnant",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "breastfeeding",
"criterion": "breastfeeding",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "pregnancy should be ruled out by an assay of βhCG plasma within 4±1 weeks prior to administration of the conjugate",
"criterion": "pregnancy test",
"requirements": [
{
"requirement_type": "timing",
"expected_value": "within 4±1 weeks prior to administration of the conjugate"
}
]
},
{
"exact_snippets": "lack of effective contraception in male or female patients with reproductive potential",
"criterion": "effective contraception",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "Colorectal cancer patients only:",
"criterions": [
{
"exact_snippets": "Colorectal cancer patients only",
"criterion": "colorectal cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Aspartate AminoTransferase, Alanine AminoTransferase, Gamma Glutamyl Transferase) or Alkaline Phosphatase levels above 5 times the or;",
"criterions": [
{
"exact_snippets": "Aspartate AminoTransferase ... levels above 5 times the",
"criterion": "Aspartate AminoTransferase levels",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">",
"value": 5,
"unit": "times the upper limit of normal"
}
}
]
},
{
"exact_snippets": "Alanine AminoTransferase ... levels above 5 times the",
"criterion": "Alanine AminoTransferase levels",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">",
"value": 5,
"unit": "times the upper limit of normal"
}
}
]
},
{
"exact_snippets": "Gamma Glutamyl Transferase ... levels above 5 times the",
"criterion": "Gamma Glutamyl Transferase levels",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">",
"value": 5,
"unit": "times the upper limit of normal"
}
}
]
},
{
"exact_snippets": "Alkaline Phosphatase levels above 5 times the",
"criterion": "Alkaline Phosphatase levels",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">",
"value": 5,
"unit": "times the upper limit of normal"
}
}
]
}
]
},
{
"line": "* Total bilirubin above 2 times the Upper Limit Normal (ULN) or; Both pancreatic and colorectal cancer patients:",
"criterions": [
{
"exact_snippets": "Total bilirubin above 2 times the Upper Limit Normal (ULN)",
"criterion": "total bilirubin",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 2,
"unit": "times ULN"
}
}
]
},
{
"exact_snippets": "pancreatic and colorectal cancer patients",
"criterion": "cancer type",
"requirements": [
{
"requirement_type": "presence",
"expected_value": [
"pancreatic",
"colorectal"
]
}
]
}
]
},
{
"line": "* Serum creatinine above 1.5 times the ULN or;",
"criterions": [
{
"exact_snippets": "Serum creatinine above 1.5 times the ULN",
"criterion": "serum creatinine",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 1.5,
"unit": "times the ULN"
}
}
]
}
]
},
{
"line": "* Absolute neutrophils counts below 1.5 x 109/L or;",
"criterions": [
{
"exact_snippets": "Absolute neutrophils counts below 1.5 x 109/L",
"criterion": "absolute neutrophils counts",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "<",
"value": 1.5,
"unit": "x 10^9/L"
}
}
]
}
]
},
{
"line": "* Platelet count below 100 x 109/L or;",
"criterions": [
{
"exact_snippets": "Platelet count below 100 x 109/L",
"criterion": "platelet count",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "<",
"value": 100,
"unit": "x 10^9/L"
}
}
]
}
]
},
{
"line": "* Hemoglobin below 4 mmol/L (females) or below 5 mmol/l (males);",
"criterions": [
{
"exact_snippets": "Hemoglobin below 4 mmol/L (females)",
"criterion": "hemoglobin",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<",
"value": 4,
"unit": "mmol/L"
}
}
]
},
{
"exact_snippets": "Hemoglobin ... below 5 mmol/l (males)",
"criterion": "hemoglobin",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<",
"value": 5,
"unit": "mmol/L"
}
}
]
}
]
},
{
"line": "* Known positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAG) or hepatitis C virus (HCV) antibody or patients with untreated serious infections;",
"criterions": [
{
"exact_snippets": "Known positive test for human immunodeficiency virus (HIV)",
"criterion": "HIV status",
"requirements": [
{
"requirement_type": "test result",
"expected_value": "positive"
}
]
},
{
"exact_snippets": "Known positive test for ... hepatitis B surface antigen (HBsAG)",
"criterion": "hepatitis B surface antigen (HBsAG) status",
"requirements": [
{
"requirement_type": "test result",
"expected_value": "positive"
}
]
},
{
"exact_snippets": "Known positive test for ... hepatitis C virus (HCV) antibody",
"criterion": "hepatitis C virus (HCV) antibody status",
"requirements": [
{
"requirement_type": "test result",
"expected_value": "positive"
}
]
},
{
"exact_snippets": "patients with untreated serious infections",
"criterion": "serious infections",
"requirements": [
{
"requirement_type": "treatment status",
"expected_value": "untreated"
}
]
}
]
},
{
"line": "* Any condition that the investigator considers to be potentially jeopardizing the patients' wellbeing or the study objectives.",
"criterions": [
{
"exact_snippets": "Any condition that the investigator considers to be potentially jeopardizing the patients' wellbeing or the study objectives.",
"criterion": "condition jeopardizing wellbeing or study objectives",
"requirements": [
{
"requirement_type": "investigator consideration",
"expected_value": "potentially jeopardizing"
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [
{
"line": "* Laboratory abnormalities defined as:",
"criterions": []
}
],
"failed_miscellaneous": []
}